Based on the Akero Therapeutics Inc stock forecast from 8 analysts, the average analyst target price for Akero Therapeutics Inc is USD 70.07 over the next 12 months. Akero Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Akero Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Akero Therapeutics Inc’s stock price was USD 35.97. Akero Therapeutics Inc’s stock price has changed by -11.14% over the past week, -14.60% over the past month and +55.51% over the last year.
No recent analyst target price found for Akero Therapeutics Inc
No recent average analyst rating found for Akero Therapeutics Inc
Company Overview Akero Therapeutics Inc
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Read Less
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects agains...Read More
Frequently Asked Questions About Akero Therapeutics Inc (AKRO) Stock
Based on ratings from 8 analysts Akero Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 14 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on AKRO's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for AKRO is USD 70.07 over the next 12 months. The maximum analyst target price is USD 109 while the minimum anlayst target price is USD 35.
AKRO stock's Price/Earning ratio is 8.18.
Our analysis grades AKRO stock's Price / Earning ratio at F. This means that AKRO stock's Price/Earning ratio is above 53% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AKRO may be a overvalued for its sector.
The last closing price of AKRO's stock was USD 35.97.
The most recent market capitalization for AKRO is USD 3.35B.
Based on targets from 8 analysts, the average taret price for AKRO is projected at USD 70.07 over the next 12 months.
This means that AKRO's stock price may go up by +105.84% over the next 12 months.
We can't find any ETFs which contains Akero Therapeutics Inc's stock.
As per our most recent records Akero Therapeutics Inc has 63 Employees.
Akero Therapeutics Inc's registered address is 601 Gateway Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Akero Therapeutics Inc's website at https://akerotx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Akero Therapeutics Inc (AKRO) Stock
Based on ratings from 8 analysts Akero Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 14 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on AKRO's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for AKRO is USD 70.07 over the next 12 months. The maximum analyst target price is USD 109 while the minimum anlayst target price is USD 35.
AKRO stock's Price/Earning ratio is 8.18.
Our analysis grades AKRO stock's Price / Earning ratio at F. This means that AKRO stock's Price/Earning ratio is above 53% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AKRO may be a overvalued for its sector.
The last closing price of AKRO's stock was USD 35.97.
The most recent market capitalization for AKRO is USD 3.35B.
Based on targets from 8 analysts, the average taret price for AKRO is projected at USD 70.07 over the next 12 months.
This means that AKRO's stock price may go up by +105.84% over the next 12 months.
We can't find any ETFs which contains Akero Therapeutics Inc's stock.
As per our most recent records Akero Therapeutics Inc has 63 Employees.
Akero Therapeutics Inc's registered address is 601 Gateway Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Akero Therapeutics Inc's website at https://akerotx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AKRO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
